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Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status 
Objective




Tertiary high-risk familial gynaecological cancer clinic 
Population/Sample
Women undergoing risk-reducing salpingo-oophorectomy between January-2005 and November-2009
Methods
Women at high-risk of ovarian/tubal cancer were identified on the basis of the inclusion criteria for the national United Kingdom Familial Ovarian Cancer Screening Study. Risk management options discussed with 1456 high-risk women included risk-reducing salpingo-oophorectomy . A strict histopathological protocol with serial slicing was used to assess tubes and ovaries.
Results
308 high-risk women (191unknown mutation status, 117BRCA1/2 carriers) chose risk-reducing surgery. 94.5% of procedures were performed laparoscopically. The surgical complication rate was 3.9%(95%CI,2.0,6.7). Four ovarian, 10 tubal occult invasive/insitu cancers were found. The overall occult invasive cancer rate was 5.1%(95%CI,1.9,10.83%) in BRCA1/2 carriers and 1.05%(95%CI,0.13,3.73%) in untested women. When tubal insitu cancers were included the overall rate was 4.55%(95%CI,2.5,7.5). Two untested women with tubal carcinoma insitu were subsequently found to be BRCA carriers. The median ages of BRCA carriers (58years,IQR-13.4) and untested women (49.5years,IQR-20.6) with occult invasive/insitu cancer were not significantly different(p=0.454).
Conclusions 
Both high-risk women of unknown mutation status and BRCA carriers have a significant (although higher in the latter) rate of occult invasive/insitu tubal/ovarian cancer with a similar age distribution at detection. The data has important implications for counselling high-risk women on the likelihood of occult malignancy and perioperative complications at risk-reducing salpingo-oophorectomy.  Women with occult disease should be offered genetic testing. 
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Inherited mutations in the BRCA1 and BRCA2 genes account for most of the known hereditary risk for breast and ovarian cancer. Published meta-analyses have found cumulative breast and ovarian cancer risks (till age 70 years) to be: up to 65% and 40% respectively for BRCA1 carriers, and up to 49% and 18% respectively for BRCA2 carriers. ADDIN EN.CITE 1-2 However, higher penetrances have been documented in carriers ascertained from high-risk families with multiple cancer cases. ADDIN EN.CITE 3-6 Risk reducing salpingo-oophorectomy is the most effective option for preventing ovarian/tubal cancer in women at high-risk for the disease, with a hazard ratio (HR) for ovarian cancer (OC) of 0.21 (95%CI 0.12, 0.39)7 in BRCA1/2 carriers. There is a persistent 4.3% residual risk of primary peritoneal cancer. ADDIN EN.CITE 8 Oophorectomy also halves the risk of breast cancer in premenopausal women.7 Varying occult cancer rates (range 0%-17%, ADDIN EN.CITE 9-14 mean 4.7%11) have been documented in BRCA carriers undergoing surgery. More recently, molecular and histological changes in tubal (particularly fimbrial) epithelium not amounting to carcinoma in situ (CIS) have been reported. ADDIN EN.CITE 15-16 However, the clinical significance of these lesions and their role in ovarian carcinogenesis is yet to be established. 

Clinical practice guidelines to select the threshold(s) of BRCA genetic testing and clinical intervention are based on cost-effectiveness, with BRCA gene testing within the UK National Health Service (NHS) being primarily available to cancer affected individuals from high-risk families (≥20% carrier probability) or individuals from a family with a confirmed BRCA mutation. As a result a number of high-risk women in the UK are unable to access gene testing as they have no live affected relative and are unaware of their mutation status. With increasing awareness a number of such women are being referred to gynaecologists for management of ovarian cancer risk. Options available to these high risk women identified on the basis of their pedigree by genetic units in the UK include participation in a national screening trial and risk-reducing surgery. 

Here we report on the surgical and histopathological outcomes including occult cancer rates following risk reducing surgery in high-risk women attending a tertiary multidisciplinary familial gynaecological cancer clinic. The uniqueness of our cohort includes the presence of a large number of women from high-risk families whose unknown mutation status was unknown in addition to confirmed BRCA carriers. Comparison of outcomes between these two groups, provide further insight into the risk of ovarian and tubal cancer risk in breast and/or ovarian cancer families.

Methods
The familial gynaecological cancer clinic at UCLH is a tertiary level clinic for managing women at ‘high-risk’ for such malignancies. The majority of the referrals are from clinical genetics teams following a family history based assessment. The multidisciplinary team includes gynaecological oncologists, clinical geneticist, clinical psychologist, radiologist, clinical nurse specialist, minimal access gynaecologist, pathologist and clinical fellow. All women attending the clinic undergo detailed pedigree based clinical risk-assessment and counselling. Women fulfilling the inclusion criteria of the UK Familial Ovarian Cancer Study (UKFOCSS) (supplemental figure-1) were deemed to be high-risk and received comprehensive advice on the advantages and disadvantages of risk reducing salpingo-oophorectomy and screening for ovarian cancer as well as reproductive and life style issues. The primary recommendation is risk reducing salpingo-oophorectomy with detailed discussion of the advantages and disadvantages.  Women >35 years age also had the option of participating in the national  ovarian cancer screening study (UKFOCSS). 

Between Jan 2005 and November 2009, 1888 women with a family history of breast and/or ovarian cancer were seen in clinic. We have excluded women whose family history fulfils Amsterdam Criteria-II and those with known mismatch repair gene mutations (suggestive of Lynch Syndrome) from this analysis. On assessment, 37 (2%) women were low-risk (≤2% life-time risk or population based risk), 217 (11.5%) were intermediate-risk (greater than population based risk but not fulfilling the high-risk criteria in supplemental table-1) and 1624 (76.7%) were high-risk for ovarian cancer. In 10 (0.53%) cases data on risk status were missing. Of 1624 high-risk women, 168 (10.3%) were <35 years and deferred decision making, 1148 (70%) preferred screening and 308 (19%) opted for preventative surgery. 40% BRCA carriers and 18% of women with unknown mutation status underwent prophylactic salpingo-oophorectomy over this period. 

All women underwent a pre-operative CA125 and transvaginal ultrasound scan (TVS). Surgery involved removal of both tubes and ovaries (or all remaining adnexae in women who had undergone previous partial removal), peritoneal washings for cytological examination and endometrial sampling. Specimens were processed by a dedicated senior pathologist (EB) with a special interest in familial gynaecological cancer. A strict surgico-pathological protocol was adopted: both tubes and ovaries were transversely sectioned at 2-3 mm intervals and processed in their entirety to exclude occult carcinoma. Histological assessment of dysplasia/atypia was based on dysplastic changes, degree of nuclear stratification, mitotic index, nuclear:cytoplasmic ratio, prominent nucleoli, and loss of ciliated cells. Cases with histological abnormalities not amounting to carcinoma insitu (CIS), but showing, some nuclear enlargement, prominent nucleoli, pseudostratification, incomplete replacement of the adjacent normal ciliated cells, less than full thickness mucosal involvement, preserved epithelial polarity, were graded as mild- moderate epithelial atypia depending on the degree of abnormality. 

Demographic, clinical and histopathological data were collected for each patient using a standardised proforma and entered prospectively in a  bespoke database. These were used for the current analysis. Where necessary, case notes as well as TVS, histopathology, cytology and biochemistry reports were reviewed. Women who had amenorrhea for > 12 months (excluding those with a medical or physiological explanation such as, Mirena IUS, hormonal therapy or breast feeding) were considered to be postmenopausal for the purpose of this analysis. Outcomes were compared between BRCA carriers and women of unknown mutation status. Statistical analysis was undertaken using SPSS 18. The Mann-Whitney non-parametric test was used to compare age distributions between groups after reviewing histograms. Chi-Square with Yate’s continuity correction (n>30) and Fisher’s test (n<30) were used to calculate the difference between proportions. Two sided p values are reported for all statistical tests. Confidence intervals for a single proportion were calculated using the ‘Measuring Usability’ statistics package (J Sauro).
. 
Results
308 women from breast and/or ovarian cancer families opted for risk reducing salpingo-oophorectomy between January 2005 and November 2009. Of these 65 (21.1%) were BRCA1 carriers, 52 (16.9%) BRCA2 carriers and 191 (62%) had an unknown mutation status. The characteristics of the cohort are described in Table-1. In 26 of the 191 women of unknown mutation status, an affected member of the family was not found to carry a pathogenic mutation on BRCA1/2 testing. 

A detailed comparison of the characteristics of women in the BRCA1/2 and unknown mutation status groups is presented in Table-2. The median age of BRCA carriers opting for risk reducing surgery (48.9, IQR 13.1 years) was significantly lower than that of women of unknown mutation status (52.1, IQR 11.7 years) undergoing surgery (p=0.016, Table-2). The groups did not differ with respect to parity or menopausal status, but did differ significantly with regards to family history of cancer: breast cancer families and personal history of breast cancer were overrepresented in BRCA carriers, whilst ovarian cancer families or a close relative with ovarian cancer were commoner in women of unknown mutation status (p<0.0005) (Table-2). 

Of the 308 surgical procedures undertaken, 74% (228) were performed at UCLH, seven at other NHS gynaecological oncology centres, six in the private sector, and the remaining at local referring NHS hospitals. 291 were completed laparoscopically (Table-1). In all cases where the ovary was not removed at surgery, previous oophorectomy had been undertaken for benign pathology. Three patients who were operated outside our institution only underwent laparoscopic bilateral oophorectomy at initial surgery. One of them subsequently underwent completion bilateral salpingectomy at our hospital. 15 patients underwent primary laparotomy: six due to multiple previous abdominal surgeries and nine for concomitant hysterectomy. In total hysterectomy was undertaken in 15 (4.9%) patients for benign pathology such as fibroid uterus, heavy periods and uterovaginal prolapse (Table-1). In two women laparoscopic surgery was converted to laparotomy due to serosal bowel injury (one) and poor visualisation due to dense adhesions (one). Four patients had intraoperative complications and eight had post-operative complications (Table-1), giving an overall complication rate of 3.9% (95%CI, 2.0,6.7%). 

Histological examination revealed 14 occult invasive/in situ cancers: four were ovarian (three primary ovarian, one recurrent breast) and 10 were primary tubal in origin (one invasive, nine CIS) (Table-3).  The overall occult cancer rate was 4.55% (CI, 2.51, 7.51). The occult ovarian/tubal cancer (invasive cancers and insitu cancers with positive cytology) rate was 2.6% (CI 1.13, 5.05%): 5.13% (CI 1.9, 10.83%) for BRCA carriers and 1.05% (CI 0.13, 3.73%) for women of unknown mutation status. When insitu tubal cancer was included the rate was 4.55% (CI, 2.51, 7.51). Six of these 14 occurred in BRCA1 carriers (occult rate 9.23%, CI 3.46, 19.02)), four in BRCA2 carriers (occult rate 7.69%, CI 2.14, 18.54) and four in women of women of unknown mutation status (occult rate 2.1%, CI 0.57, 5.28). The occult invasive/insitu cancer rate for both BRCA1/2 carriers (8.55%, CI 4.17,15.16) was significantly higher than that of women with unknown mutation status (p=0.016) (Table-2). 

Of the four women of unknown mutation status with occult insitu/invasive cancers, two women with tubal CIS were subsequently found to carry a BRCA1 and BRCA2 mutation respectively on genetic testing following histology and in two others, an affected relative had previously tested negative for BRCA1/2 mutations. Of the latter two women, the first had a strong family history of breast and ovarian cancer: epithelial ovarian cancer in her mother age 62 and maternal aunt age 49; breast cancer in three maternal aunts aged 43, 46 and 50 years; colorectal cancer in a maternal aunt age 47 years; breast cancer in her grand aunt age 60 years). The second had a strong family history of breast cancer: breast cancer herself age 30 years, breast cancer in her paternal grandmother age 60 and paternal aunt age 45 years. None of the four women of unknown mutation status had a primary invasive ovarian cancer though a metastatic ovarian cancer consistent with a breast primary was found in one. 

Of the primary invasive cancers four were stage-1 (three fallopian tube, one ovarian cancer), one (ovarian cancer) was stage-2 (Table-3). Of the 10 tubal lesions nine were CIS and one was a stage1a invasive cancer. Of the nine CIS cases, two with tubal CIS had adenocarcinoma on peritoneal cytology and one had cytology suspicious of malignancy. However, no focus of primary cancer was identifiable even after full staging surgery and completion hysterectomy in these patients. The median age of patients with occult primary insitu/invasive cancer (56 years, IQR 16.1) was not statistically significantly different from the rest of the cohort (50.4 years, IQR 11.8) (p=0.433). No statistically significant difference was found between the median ages of women of unknown mutation status (49.5 years, IQR 20.6) and BRCA carriers (58 years, IQR 13.4) with occult invasive/insitu cancer (p= 0.454).

We also found mild-moderate tubal atypia not amounting to CIS / serous tubal intra-epithelial carcinoma (STIC) in one/both tubes of 10 other women, of whom three were BRCA1 carriers, two were BRCA2 carriers and five had unknown mutation status (Table-4). The overall mild to moderate tubal atypia rate  was 3.57% (CI 1.8, 6.3%). This was not statistically significantly different (p=0.768) for BRCA1/2 carriers (4.27%, CI 1.4, 9.69%) or those with unknown mutation status (3.14%, CI 1.16, 6.71%).  37 (12%) women had other incidental benign pathology (without atypia) of the tubes/ovaries. There was no difference in benign pathology rates between BRCA1/2 carriers and patients of unknown mutation status.

Discussion
Our study shows that at risk reducing salpingo-oophorectomy, high-risk women from breast and/or ovarian cancer families without a confirmed BRCA mutation have a 1.05% (CI 0.13, 3.73%) risk of  occult cancer while those with confirmed BRCA1/2 mutations have a  5.13% (CI 1.9, 10.83%).  When tubal carcinoma in-situ  lesions were included the rates were higher, 2.1%, ( 95%CI 0.57, 5.28) in women of unknown mutation status and  8.55% (CI 4.2, 15.2) in BRCA carriers. The latter is consistent with other reports in the literature. ADDIN EN.CITE 9, 11-12, 17
On reviewing the literature we found six small series (Table-5) which included outcomes of preventative surgery using a strict histopathological protocol in women from high-risk families where the BRCA mutation status was not known prior to surgery. ADDIN EN.CITE 11, 17-22 Occult neoplasia was reported in five of 68 women of unknown mutation status undergoing risk reducing salpingo-oophorectomy (Table-5). This includes three women with occult  cancers reported by Lu et al where BRCA1/2 mutations were found at testing following surgery.21 Combining our data (four occults, 191 cases) with these reports, the overall occult invasive/insitu cancer rate for those with unknown mutation status was 3.1% (CI 1.30, 6.0). If we include two studies ADDIN EN.CITE 23-24 which did not follow a strict pathological protocol the occult rate falls to 2.6% (95%CI 1.1, 5.1). Overall these data suggest that women from high-risk families where genetic testing has not been undertaken may also have high occult cancer rates. This is an important issue which affects a significant proportion of women seen in our clinics (who have not undergone BRCA testing), and our findings will facilitate more informed counselling and decision making in these cases.

The majority (71.4%; 10/14) of occult invasive/insitu cancers in our series occurred in the fallopian tube. In line with other series11,  five of these were found in BRCA1, two in BRCA2 carriers and three in women of unknown mutation status. In addition we found adenocarcinoma on peritoneal washings in two women (BRCA1 carrier, untested) with tubal CIS and suspicious cytology in one (BRCA2 carrier) with no evidence of invasion. Subsequent full staging surgery did not reveal any additional pathology. Our findings along with that of other similar reports in the literature serve to emphasise the importance of peritoneal washings in all high-risk women undergoing risk reducing surgery. ADDIN EN.CITE 19, 25 

For many years the most durable hypothesis has been that epithelial ovarian cancer arises from the ovarian surface epithelium. More recent research largely driven by such findings in the high-risk population, has led to the fallopian tube being considered an integral part of new models proposed for ovarian carcinogenesis. ADDIN EN.CITE 16, 26-27 Carcinoma insitu has been described as a precursor lesion and found to be present as a continuum with early tubal carcinomas, supporting transition from one to another.28  It has been postulated that genotoxic injury is more likely to lead to progression of these lesions to cancer in women at high risk for disease.26  Nevertheless, the clinical significance of these early precursor lesions and details of any putative molecular pathway have yet to be established. Our findings support the hypothesis that a number of ovarian cancers in BRCA carriers may arise in the fallopian tube/ extrauterine mullerian epithelium. They also suggest that the same holds true for high-risk women with unknown mutation status and women with occult invasive/insitu cancer in this group should be offered mutation testing. 

The age distribution of women of unknown mutation status with occult invasive/insitu cancer was similar to that of mutation carriers. However, the former may delay surgery till an older age. The median age of BRCA carriers undergoing RRSO was 48.9 years, which is consistent with other reports in the literature. ADDIN EN.CITE 17, 19 and in keeping with a positive BRCA genetic test result being a predictor of risk reducing surgery. ADDIN EN.CITE 29-30 However, women with unknown mutation  status underwent surgery at a significantly older median age of 52.1 years (p=0.016), which has important implications for counselling. 

This is to the best of our knowledge the largest series to date reporting outcomes in high-risk women from breast/ovarian or ovarian cancer families who have not undergone BRCA testing (Table-5). Previous series have focused largely on BRCA carriers, ADDIN EN.CITE 8, 10, 13, 31 with only limited outcome data available on women from high-risk families where genetic testing has not been undertaken. ADDIN EN.CITE 11, 17, 19-24 Other strengths of our study include prospective data collection using standardised proforma, strict histopathological assessment of removed tubes and ovaries and strict definition of high risk using accepted definitions adopted in the UK  high risk screening trial (UKFOCSS).  A limitation of our study is that BRCA status of women in the unknown mutation status group is not obtainable given the current testing guidelines in UK. Availability of these data would have enabled us to comment on histopathological outcomes of BRCA negative high-risk women. 

94.5% of the preventative surgeries were completed laparoscopically, and included six of the 15 women who had a concomitant planned hysterectomy. The laparoscopic bowel injury rate of 0.32% (CI 0.01,1.8) is consistent with the incidence of bowel injury reported by others.32 The laparotomy conversion rate (0.65 %, CI 0.08, 2.33%) and overall complication rate (3.9%, CI 2.03, 6.71%) is similar to other reports in the literature. ADDIN EN.CITE 23, 31 Of the 12 patients who had surgical complications, seven were major (2.27%, CI 0.92%, 4.63%). Meeuwissen described a major complication rate of 1.5% and minor complication rate of 10% in 133 high-risk women undergoing RRSO, while Kauff reported a major complication rate of 5% in 80 cases. ADDIN EN.CITE 23, 31 Whilst RRSO is well established as the most affective means of preventing ovarian/tubal cancer in high-risk women, ADDIN EN.CITE 7, 33 it is important patients are counselled about this not insignificant risk of complications prior to surgery.
    
Uptake rates for risk reducing salpingo-oophorectomy vary between different populations. ADDIN EN.CITE 34-35 While a number of studies report higher uptake rates36, in others  ADDIN EN.CITE 29-30 similar rates to ours have been reported. Our lower RRSO uptake rates reflect our referral pattern. As we have a longstanding interest in ovarian cancer screening, women who specifically wish to participate in screening are more likely to be referred from the regional genetic centres with a proportion of those who choose RRSO having surgery at their local hospital.
The finding of occult cancer found in two of 26 women whose relative tested negative for BRCA1/2 mutations lends support to the importance of offering preventative surgery to high risk BRCA1/2 mutation negative breast and ovarian / ovarian cancer only families. It is consistent with the presence of phenocopies and the possibility of other unidentified genetic variants contributing to cancer risk in these families. The differences found in BRCA and unknown mutation status groups with respect to family history (Table-2) reflect rules governing genetic testing in the UK in the last decade which require initial testing in a live cancer affected individual in the family, and the different survival rates for breast and ovarian cancer. Unlike breast cancer, ovarian cancer is usually late stage with overall 5-year survival of 30-40%.37 Women from hereditary breast cancer alone (HBC) families are therefore more likely to have living affected relatives who can undergo genetic testing under NHS rules and hence, are significantly overrepresented in the BRCA group. However, in hereditary ovarian cancer only (HOC) or hereditary breast and ovarian cancer (HBOC) families, there are likely to be fewer living affected relatives who can undergo genetic testing. Hence, women from HOC/HBOC families are more likely to belong to the unknown mutation status group.  The same reasons are likely to explain (a) the overrepresentation of individuals with a personal history of breast cancer (p<0.0005), a first degree relative (FDR) with breast cancer (p=0.006) and a history of early breast cancer in the family (p<0.0005) in the BRCA group as well as, (b) the higher prevalence of women with a FDR with OC  (p<0.0005) and early onset OC in the family (p=0.029) in the unknown mutation status group. We also analysed whether over representation of HOC/HBOC families in the unknown mutation status group could be due to an increased uptake rate of risk reducing surgery by women from these families in the entire cohort (data not shown). However, the presence of a family history of ovarian cancer (HBOC/HOC family) was not associated with an increased uptake of RRSO in the cohort 

A number of guidelines suggest genetic testing may be of value at BRCA probability >10%. ADDIN EN.CITE 38-39 The current threshold of 20% BRCA probability for genetic testing set by NICE (National Institute for Clinical Excellence)40 may be too high and there is a need for this to be revisited. Two women in our series with unknown mutation status were subsequently found to have a BRCA mutation when tested after being found to have tubal CIS . Our findings raise the issue of giving serious consideration to the possibility of offering genetic testing to individuals in the UK from HBOC/HOC families who do not have living affected relatives and have been unable to access genetic testing. 

Conclusion
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Table 1: Characteristics of high-risk women undergoing risk reducing salpingo-oophorectomy

*Requiring resuscitation and a day’s ICU admission
** Treated with appropriate antibiotics (one showed methicillin-resistant staphylococcus aureus on culture)
# Bowel was viable and did not require resection. It was reduced and the rectus sheath defect sutured.
BSO- bilateral salpingo-oophorectomy, B/L- bilateral, C/L- contra-lateral, FDR – first degree relative, IQR- inter quartile range, LAVH- laparoscopic assisted vaginal hysterectomy, SO- salpingo-oophorectomy, TAH- total abdominal hysterectomy, TLH- total laparoscopic hysterectomy, U/L – unilateral 
Table 2: Comparison of demographics in BRCA carriers and women of unknown mutation status undergoing risk reducing salpingo-oophorectomy







Table 3: Detailed findings in the 14 occult cancers detected at risk reducing salpingo-oophorectomy







Table 4: Mild-moderate atypia not amounting to carcinoma insitu

b/l bilateral, c/l- contra lateral, CIS- carcinoma insitu, FT- fallopian tube, HBC – high-risk breast cancer only family, HBOC- high-risk breast and ovarian cancer family, i/l - ipsi lateral, UMS- unknown mutation status, u/l - unilateral

Table 5: Risk reducing salpingo-oophorectomy series# which include outcomes in high-risk women not known to carry BRCA1 / BRCA2 mutations 

 
*All 3 cancers were found to be BRCA1/2 carriers on testing postoperatively and 10 remained untested. 
**May include some data from Leeper et al
Adenoca- adenocarcinoma, BOT- borderline ovarian tumor, b/l- bilateral, BO- bilateral oophorectomy, BSO- bilateral salpingo-oophorectomy, CIS- carcinoma insitu, FT- fallopian tube, HR- high risk, inv- invasive, NA- not applicable, Neg- negative, Pap- papillary, u/l- unilateral, VUS- variant of uncertain significance.
# Includes series following a strict histopathological protocol


Figure 1: Criteria for women at high-risk of ovarian cancer
Based on the inclusion criteria of the United Kingdom Familial Ovarian Cancer Screening Study (UKFOCSS)
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